Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.

Researchers at King's College London have discovered that an immune protein best known for protecting the body against ...

We look forward to sharing additional Phase 1/2 data next week at the Muscular Dystrophy Association's annual meeting and ...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG ...